Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $5.46M
• Dividend Yield: N/A
• Average Volume (3M): 105.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 3,814,853
• 10 Day Avg. Volume: 170,679
• 30 Day Avg. Volume: 105,896
• PEG Ratio: -12.69
• Price to Book (P/B): 285.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -260.61
• Enterprise Value/Market Cap: 858.17
• Enterprise Value/Revenue: 1.51K
• Enterprise Value/Gross Profit: 8.14K
• Enterprise Value/Ebitda: -62.34
• 1Y Price Target: $14.00
• Price Target Upside: 879.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: $1.50 ▲(4.90%Upside)

The overall stock score for Mainz Biomed B.V. is primarily impacted by significant financial challenges and bearish technical indicators. The company faces high leverage, negative profitability, and reliance on financing, which are major risks. Additionally, poor valuation metrics further contribute to the low score. Immediate strategic improvements in revenue and cost management are necessary for improvement.

Positive Factors

Market Opportunity

Existing tests with a similar format, such as Cologuard, have achieved commercial success with over $2B in annual sales, presenting an opportunity for Mainz Biomed to capture share.

Product Potential

Mainz Biomed's Next Generation Test uses mRNA and FIT to enhance detection rates for advanced adenomas, showing improved results compared to industry standards.

Strategic Partnerships

Decentralized commercial strategy includes partnering with lab groups to reduce marketing and infrastructure expenses, and gain access to large physician networks.

Negative Factors

Clinical Trials

Mainz also continues to make progress in its eAArly DETECT 2 feasibility study for its next generation colorectal cancer (CRC) early screening test.

Market Competition

The feasibility study seeks to evaluate the panel and machine learning algorithm in a clinical sample set to determine sensitivity, specificity, and consistency, as well as the algorithm's ability to stratify risk.

Unmet Medical Need

Pancreatic cancer detection is an area of significant unmet need, with 67k cases in the US each year, the majority of which are caught at Stage 4.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

How the Company Makes Money

Mainz Biomed generates revenue through the sale of its proprietary diagnostic tests to healthcare providers, clinics, and laboratories. The company's primary revenue stream is derived from the commercialization of its flagship colorectal cancer screening test. Additionally, Mainz Biomed engages in strategic partnerships and collaborations with research institutions and healthcare organizations to enhance and expand its diagnostic offerings. These partnerships may contribute to revenue through joint development agreements, licensing deals, and the sharing of research findings that support product innovation and market expansion.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. faces significant financial challenges, notably negative profitability and high leverage. While there are improvements in equity and free cash flows, the company's profitability remains pressured by negative margins and reliance on external funding.

Income Statement

Mainz Biomed B.V. has shown fluctuating revenues with recent stagnation, failing to surpass the 2020 revenue levels. Despite some improvement in gross profit margins, the company continues to incur substantial EBIT and net losses, indicating persistent profitability challenges. Net profit margin remains deeply negative, emphasizing ongoing financial hurdles.

Balance Sheet

The company exhibits high leverage with a rising debt-to-equity ratio, indicating potential financial risk. Stockholders' equity has improved recently, but overall equity is still relatively low compared to total assets, suggesting limited financial stability. Return on Equity remains negative, reflecting unprofitability.

Cash Flow

Operating cash flow has been consistently negative, although free cash flow has shown some improvement. Financing activities have been a major source of cash, highlighting reliance on external funding. The operating cash flow to net income ratio is concerning, as cash flows are not covering net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	893.99K	895.48K	529.88K	577.35K	493.56K
Gross Profit	574.88K	509.66K	182.15K	177.62K	123.08K
EBITDA	-19.56M	-25.01M	-25.72M	-11.28M	-257.64K
Net Income	-21.65M	-26.30M	-26.45M	-12.07M	-886.18K
Balance Sheet
Total Assets	13.24M	15.41M	20.24M	10.04M	673.27K
Cash, Cash Equivalents and Short-Term Investments	6.24M	7.07M	17.14M	8.73M	122.57K
Total Debt	3.27M	7.42M	3.23M	2.58M	2.98M
Total Liabilities	7.19M	12.16M	6.14M	3.68M	3.41M
Stockholders Equity	6.05M	3.25M	14.10M	6.36M	-2.74M
Cash Flow
Free Cash Flow	-17.34M	-23.84M	-15.43M	-3.24M	-478.42K
Operating Cash Flow	-17.09M	-21.94M	-14.77M	-3.22M	-468.74K
Investing Cash Flow	-198.82K	-1.90M	-658.48K	1.20M	-9.69K
Financing Cash Flow	16.60M	14.23M	23.94M	10.61M	396.68K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 1.43 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 2.18, and below the 200-day MA of 5.70, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 27.73 is Positive, neither overbought nor oversold. The STOCH value of 48.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	65 Neutral	$18.22M	―	-25.29%	―	26.67%	44.02%
Sector *	64 Neutral	€7.32B	20.88	0.61%	1.91%	1.18%	-29.88%
INBS	62 Neutral	$12.30M	―	-126.34%	―	3.87%	91.76%
TRIB	49 Neutral	$13.94M	―	77.20%	―	8.31%	9.98%
BIAF	42 Neutral	$7.75M	―	-290.85%	―	78.40%	22.41%
BNGO	41 Neutral	$11.34M	―	-127.82%	―	-24.04%	84.11%
MYNZ	41 Neutral	$5.46M	―	-809.29%	―	―	―